Society of Interventional Oncology shared a post on LinkedIn:
“We’re pleased to announce the official start of patient enrollment for the TRIBUTE Trial.
This important milestone was first achieved by Northside Hospital, where Jason Levy MD, FSIR, and Mudit Chowdhary, MD, the site’s principal investigators, enrolled the inaugural patient on 23 October 2025.
Shortly after, Washington University School of Medicine in St. Louis joined the effort, enrolling its first patient on 27 October 2025 under the leadership of site study principal investigators Resten Imaoka, MD, and Joanna Yang, MD, MPH.
The TRIBUTE Trial represents a significant step forward in advancing care for patients with complex bone metastases. Stay tuned for more updates as we work together to improve patient outcomes.
Sushil Beriwal, Vice president at Varian, shared this post, adding:
“Varian supported study to help with evidence to see if combination of ablation and RT is better for high risk bone metastases.”
More posts featuring Sushil Beriwal.